ANTIBODY-DRUG (ADC)
CHARACTERIZATION SERVICE
CHARACTERIZATION SERVICE
Phase-Appropriate ADC Characterization for Development, Comparability, Validation, and Commercialization
Antibody-drug conjugates (ADCs) combine the molecular complexity of biologics with the potency of highly active small-molecule payloads. Variability in drug-to-antibody ratio (DAR), aggregation, charge heterogeneity, glycosylation, and free payload levels can directly impact safety, efficacy, pharmacokinetics, and comparability. Effective antibody drug conjugate analysis requires robust characterization of relevant quality attributes, and product-specific definition of critical quality attributes (CQAs).
At nuvalore, we provide ADC characterization and GMP-aligned analytical services to help sponsors characterize, monitor, and control CQAs throughout development, comparability assessments, validation, and commercialization.
Our capabilities include DAR analysis, charge variant analysis, peptide mapping, impurity profiling, and GMP quality control testing. Orthogonal ADC characterization can integrate chromatographic, electrophoretic, and mass spectrometry-based approaches, depending on the analytical question, product complexity, and stage of development.
By combining orthogonal analytical techniques, Quality by Design (QbD) principles, and GMP execution, we help sponsors generate reliable data, support informed comparability decisions, and advance ADC programs with confidence.
Why ADC Characterization Matters
Robust ADC analytical characterization is essential to:
- Understand and control ADC heterogeneity
- Support stability and comparability assessments
- Monitor product consistency throughout development
- Generate data suitable for validation and GMP quality control
- Build confidence in regulatory submissions and lifecycle management
As ADC programs advance from early development into validation, stability studies, and commercial manufacturing, analytical requirements become increasingly demanding. Phase-appropriate analytical strategies help ensure methods remain fit-for-purpose throughout the product lifecycle.
Supporting ADC Programs Across the Lifecycle
ADC Physicochemical Characterization Built Around Product-Relevant Quality Attributes
| Analytical Focus Area | Critical Quality Attribute (CQA) | Why It Matters | Primary Analytical Techniques |
|---|---|---|---|
| Drug-to-Antibody Ratio (DAR) | DAR average & DAR distribution | A major determinant of the efficacy-toxicity balance and a key indicator of conjugation consistency, product stability, and lot-to-lot reproducibility | HIC-HPLC, RP-HPLC, LC-MS* |
| Size Variants & Purity | Aggregates, fragments, and purity | Aggregation and fragmentation can impact safety, pharmacokinetics, and immunogenicity risk; critical for release, stability, and product consistency | SEC-HPLC, CE-SDS, SEC-MALS |
| Charge Variant Analysis | Charge heterogeneity | Sensitive indicator of conjugation-induced heterogeneity and process consistency; supports stability studies, comparability assessments, and lifecycle monitoring | icIEF, CEX |
| Identity & Primary Structure | Identity confirmation and PTM trending | Verifies molecular integrity, monitors PTM trends, and supports stability, comparability, and root-cause investigations | UV-RP-HPLC Peptide Mapping, LC-MS* |
| Free Payload & Related Impurities | Unconjugated payload and degradation products | Critical for controlling toxicity risk and supporting release and stability testing | Payload-related impurity profiling using fit-for-purpose chromatographic methods |
| Glycosylation Profiling | N-glycosylation patterns | Glycosylation can influence Fc-mediated functions and alter charge or hydrophobicity profiles, supporting process consistency monitoring and comparability assessments | Released glycan profiling by RP-HPLC, HILIC |
| Mass Spectrometry Characterization | PTMs, DAR species, conjugation site, structural integrity | Provides high-resolution characterization of ADC heterogeneity, supporting DAR species analysis, conjugation site assessment, PTM monitoring, root-cause investigations, and high-confidence comparability assessments | LC-MS*, Subunit LC-MS*, Native LC-MS*, Reduced LC-MS* |
*LC-MS capabilities are currently being expanded as part of nuvalore’s analytical platform development. Please contact us to discuss project-specific requirements.
Comparability-Ready Analytical Strategies
Process changes, manufacturing scale-up, site transfers, formulation updates, and lifecycle improvements all require robust comparability assessments.
nuvalore designs comparability-ready analytical strategies that evaluate critical quality attributes across multiple dimensions of product quality. By combining complementary analytical approaches, we help sponsors assess the impact of process changes, demonstrate product consistency, and support informed development and commercialization decisions.
Our analytical strategies support alignment with:
- ICH Q5E (Comparability)
- ICH Q6B (Specifications)
- ICH Q2(R2) (Validation)
- ICH Q14 (Analytical Procedure Development)
- EU GMP expectations
GMP Quality Control & Release Testing
Beyond analytical characterization, nuvalore supports GMP quality control and release testing activities required for clinical and commercial ADC drug products.
Our capabilities include:
- Appearance
- Color
- pH
- Conductivity
- Osmolality
- Visible particles
Performed within our GMP-certified quality control laboratory using applicable pharmacopoeial methods and GMP procedures, these tests support batch release, stability programs, and ongoing quality control throughout commercialization.
Advance Your ADC Program with Confidence
Whether you are establishing analytical control strategies for a new ADC, preparing for validation, supporting comparability after process changes, or implementing GMP quality control testing, nuvalore provides the analytical expertise and execution needed to support informed development and commercialization decisions.
Frequently Asked Questions
Companies choose nuvalore for its GMP-certified pharmaceutical QC environment, orthogonal analytical strategies, phase-appropriate analytics, QbD-driven method design, and regulatory alignment. The team tailors comprehensive ADC analytical services to program timelines, supporting development, comparability, validation, and commercialization with reliable, actionable data.
nuvalore applies orthogonal analytical strategies, combining DAR analysis, peptide mapping, mass spectrometry, charge variant analysis, glycan profiling, and size variant analysis to cross-validate findings and increase confidence. Methods are developed and executed using Quality by Design (QbD) principles and GMP practices, aligning with program goals and regulatory expectations to support high-confidence comparability assessments and informed development decisions.
nuvalore centers analytics on CQAs tied to safety, efficacy, and consistency and uses fit-for-purpose techniques:
- Drug-to-Antibody Ratio (DAR): HIC-HPLC to determine average DAR and distribution.
- Size Variants and Purity: SEC-HPLC and CE-SDS for aggregates, fragments, and purity.
- Charge Variants: icIEF and CEX for charge heterogeneity.
- Identity and Primary Structure: UV-RP-HPLC peptide mapping for identity and PTM trending.
- Free Payload and Related Impurities: Chromatographic impurity profiling to control toxicity risk.
- GMP Quality Control Testing: USP/EP methods (appearance, color, pH, conductivity, osmolality, and visible particles) supporting batch release and ongoing quality control.
- Glycosylation Profiling: RP-HPLC and HILIC glycan mapping for process consistency and comparability.
- Mass Spectrometry Characterization*: Intact/subunit/native/reduced LC-MS for PTMs, DAR species, conjugation sites, and structural integrity.
nuvalore provides phase-appropriate analytics from early development through commercialization. Early development focuses on product characterization, CQA identification, method development, early stability, and conjugation characterization. During clinical development, the team executes stability studies, method qualification, comparability assessments, process monitoring, and characterization of development batches. For commercial readiness, nuvalore performs method validation and transfer, GMP QC testing and release support, and ongoing stability programs.
Antibody-drug conjugates are inherently heterogeneous. Attributes like DAR, aggregation, charge variants, glycosylation, and free payload levels directly influence safety, efficacy, pharmacokinetics, and comparability. Robust, phase-appropriate characterization enables stability testing, monitors product consistency, supports comparability assessments, generates validation- and GMP-ready data, and builds confidence for regulatory submissions and lifecycle management.
nuvalore GmbH
Paul-Ehrlich-Str. 1
D – 69181 Leimen
Phone
+49 (6224) 179 966 0
